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Abstract
Background: The cardiovascular risk in renal transplant patients is increased in patients who continue to smoke
after transplantation.
The aim of the study is to measure the effectiveness of exhaled carbon monoxide (CO) measurement plus brief
advisory sessions, in comparison to brief advice, to reduce smoking exposure and smoking behavior in kidney
transplant recipients who smoke. The effectiveness will be measured by: (1) abandonment of smoking, (2) increase
in motivation to stop smoking, and (3) reduction in the number of cigarettes smoked per day.
Methods/design: Design: a randomized, controlled, open clinical trial with blinded evaluation.
Scope: A Coruña Hospital (Spain), reference to renal transplantation in the period 2012–2015.
Inclusion criteria: renal transplant patients who smoke in the precontemplation, contemplation or preparation
stages according to the Prochaska and DiClemente’s Stages of Change model, and who give their consent to
participate.
Exclusion criteria: smokers attempting to stop smoking, patients with terminal illness or mental disability that
prevents them from participating.
Randomization: patients will be randomized to the control group (brief advisory session) or the intervention group
(brief advisory session plus measuring exhaled CO). The sample target size is n = 112, with 56 patients in each
group. Allowing for up to 10 % loss to follow-up, this would provide 80 % power to detect a 13 % difference in
attempting to give up smoking outcomes at a two-tailed significance level of 5 %. Measurements: sociodemographic
characteristics, cardiovascular risk factors, treatment, rejection episodes, infections, self-reported smoking habit, drug
use, level of dependence (the Fagerström test), stage of change (Prochaska and DiClemente’s Stages of Change
model), and motivation to giving up smoking (the Richmond test).
Response: the effectiveness will be evaluated every 3, 6, 9 and 12 months as: pattern of tobacco use (self-reported
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tobacco use), smoking cessation rates, carbon monoxide (CO) levels in exhaled air measured by CO-oximetry, urinary
cotinine tests, nicotine dependence (Fagerström test), motivational stages of change (Prochaska and DiClemente’s
stages) and motivation to stop smoking (the Richmond test).
Analysis: descriptive statistics and linear/logistic multiple regression models will be performed. Clinical relevance will be
measured as relative risk reduction, absolute risk reduction and the number needed to treat.
Ethics: informed consent of the patients and Ethical Review Board was obtained (code 2011/061).
Discussion: Tobacco is a modifiable risk factor that increase the risk of morbidity and mortality in kidney transplant
recipients. If effectiveness of CO-oximetry is confirmed to reduce tobacco exposure, we would have an intervention
that is easy to use, low cost and with great implications about cardiovascular risk prevention in these patients.
Trial registration: Current Controlled Trials ISRCTN16615772.
EudraCT number: 2015-002009-12.
Keywords: Smoking cessation, Carbon monoxide, Nicotine dependence, Kidney transplantation
Background
Cigarette smoking is a well-established risk factor for car-
diovascular disease and cancer [1]. An adverse effect of
smoking on renal function has also been described. Al-
though the exact mechanisms of smoking-induced renal
damage remain to be determined, there is clinical evidence
that smoking has important adverse effects on renal out-
come in various kidney diseases, such as diabetic nephrop-
athy, hypertensive kidney disease, and primary glomerular
diseases, as well as for patients who require hemodialysis
chronically [2–4]. In renal transplant recipients, who
already have a higher risk of cancer [5, 6] and cardiovascu-
lar disease [7] than the general population, smoking should
probably be viewed as an even more risky behavior.
Despite its well-known harmful effects, smoking preva-
lence is still high, predominantly in developing countries.
The latest World Health Organization (WHO) population
survey demonstrated a 29 % rate of smoking in adults in
Europe [8]. In Spain, the 2006 National Health Survey
(NHS) estimated a 29.5 % smoking rate in adults aged
16 and over [9], with approximately 53,155 smoking-
attributable deaths in the same year [10]. Smoking preva-
lence among kidney transplant recipients is more difficult
to estimate, and varies greatly across studies [11]. In a previ-
ous work, we found that up to 41.7 % of the renal trans-
planted patients in our center were smokers at the time of
transplantation, and about 15 % continued smoking after
the transplant [12]. Although this figure is not very high,
the impact of smoking habit on the probability of cardiovas-
cular events in the follow-up of kidney transplant recipients
is clinically relevant. As stated in a previous paper, at the 5-
year and 10-year follow-up, the number of patients needed
to treat (NNT) who would have to give up smoking to pre-
vent a cardiovascular event was 7 and 4, respectively [13].
A recent review [11] identified 12 studies in the period
1968–2009 reporting the effect of cigarette smoking on
kidney allograft or recipient survival [14–25]. Although
some of the revised studies showed contradictory results,
in general cigarette smoking was associated with an in-
creased risk of both graft loss and death. More recently,
a large-scale study investigated the effect of smoking on
post-kidney transplant outcomes in a retrospective co-
hort of 41,705 adult renal transplant recipients in the
United States Renal Data System [26]. That work con-
cluded that, compared with patients who have never
smoked, new onset smoking after transplantation is as-
sociated with reduced allograft and patient survival.
Similarly, a prospective study of 604 renal transplant
recipients in The Netherlands showed that smoking after
renal transplantation increases the risk of graft failure
and mortality, while past smoking is a risk factor for
mortality but not for graft failure [27]. Another European
recent study in 402 randomly selected kidney graft recipients
also concluded that smoking is a risk factor for kidney dam-
age following renal transplantation [28].
Although there is evidence that active smoking plays
an important role in allograft loss and patient mortality,
this information has so far had little impact on patient
management. Based on these results, smoking cessation
should be promoted among patients undergoing kidney
transplantation.
Both pharmacotherapy and non-pharmacological in-
terventions could be used for the treatment of tobacco
dependence. Non-pharmacological methods have the
advantage of being inexpensive and feasible to implement,
and may be particularly appropriate for transplant pa-
tients, who are usually polymedicated. The main non-
pharmacological interventions for the treatment of to-
bacco dependence include advice from health profes-
sionals, self-help material, proactive telephone counseling,
group or individual counseling, and intra-treatment or
extra-treatment social support.
Although smoking cessation advice from a health pro-
fessional improves smoking cessation rates, it is only
moderately effective, with a smoking cessation rate only
1 to 3 % higher [29]. An alternative to increase smoking
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cessation rates could be to provide the patients with feed-
back on the physical effects of smoking via physiological
measurements, such as measurement of carbon monoxide
(CO) levels in exhaled air by CO-oximetry. Although a
recent review could not demonstrate a significant benefit
of interventions based on biomedical risk assessments,
there is still insufficient evidence regarding this issue [30].
Furthermore, there is scarce data exploring the effect of
these kinds of interventions on hospitalized patients
or acutely ill patients. It is possible that such a specific
context and the presence of co-existent illnesses could
facilitate a modification of risk perception.
Currently, different projects are trying to determine
the efficacy of adding spirometry or CO-oximetry in-
formation to brief advice on smoking cessation, in the
primary health care setting [31, 32]. Measuring the
level of CO in smokers’ exhaled air can motivate them
to stop smoking or be a useful tool in monitoring their
progress towards cessation. We aim to test its effi-
ciency in a more restricted setting, studying its utility
to promote smoking cessation among kidney trans-
planted patients. The objective of this study is to
measure the effectiveness of exhaled CO plus brief
advisory sessions, in comparison to brief advice, to
reduce smoking exposure and smoking behavior in
kidney transplant recipients who smoke. The effective-
ness will be measured by:
1. Self-reported tobacco use: abandonment of smoking
habit and change in the number of cigarettes per
day smoked
2. Abandonment of smoking habit confirmed through
a urinary cotinine test
3. Variation in the motivational stages of change,
according to the Prochaska and DiClemente’s
Stages of Change model [33]
4. Change in the motivation to giving up smoking,
according to the Richmond test [34]




This will be a single-centre prospective, randomized, con-
trolled and open clinical trial with parallel groups set in
the Nephrology Department at the Complexo Hospitalario
Universitario A Coruña (northwest Spain). This is a 1382-
bed public tertiary care hospital attending a population of
nearly 560,000 habitants. The Nephrology department at
Complexo Hospitalario Universitario de A Coruña is a ref-
erence hospital for renal transplantation at national level.
Study period
Four years (from January 2012 to December 2015).
Study population
All renal transplanted patients attending specialized con-
sultations at the Nephrology department during the
study period, who meet the inclusion criteria, are eligible
to participate in the study. The flowchart of the study is
shown in Fig. 1.
Inclusion criteria
 Adult (over 18 years of age) kidney transplant
recipients who smoke, with functioning allograft,
who underwent primary or repeated renal
transplantation from a cadaveric or a living donor in
the A Coruña Hospital between 1981 and 2014
 Current daily smokers. Smoking status is defined
according to the WHO classification. Therefore, a
patient is considered a current daily smoker if they
report daily smoking during the previous month,
irrespective of the number of cigarettes smoked
 Patients in the precontemplation, contemplation or
preparation stages, based on Prochaska and
DiClemente’s transtheoretical model [33]
Smokers in the precontemplation stage have not ser-
iously considered giving up smoking and do not think
they will do so within the next 6 months. For the
individual the pros of continuing smoking clearly out-
weigh the cons. They can be in this condition because
they are misinformed or poorly informed about the con-
sequences of their conduct or because they have tried to
change it several times and are demoralized because they
were not able to do so. They tend to avoid reading,
speaking or thinking about the risk. Smokers in the
contemplation stage have seriously considered giving
up smoking within the next 6 months. They have not
considered giving up smoking within the next 30 days
or have not tried to stop for at least 24 h in the last
year. They worry about the risks, their motivation to
change or to remain without changing, and also their
intention of changing in the long term, within the
next 6 months but without specifying when. The
smokers in the stage of preparation for the action
have considered giving up smoking within the next
30 days, besides having made an attempt to abandon
the habit for a duration of at least 24 h in the last
year. Otherwise, they will be said to be in the stage
of contemplation.
Exclusion criteria
 Adult kidney transplant recipients whose grafts have
failed
 Non-smoker and former smoker kidney transplant
recipients
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 Patients in the action stage on Prochaska and
DiClemente’s transtheoretical model [33]
 Patients with any chronic or terminal condition that
complicates the study interventions
 Patients with mental illness or transitory psychiatric
deterioration at the moment of inclusion, who are
not able to understand the study or complete the
informed consent
Recruitment of subjects
All renal transplanted patients will be contacted during
their medical consultations at the hospital. They will be
asked about their smoking habit. The patients who de-
clare themselves smokers will be informed about the
aims of the study and will be offered the chance to take
part in it. An information sheet will be provided and
informed consent will be obtained.
They will be asked about their consumption of tobacco
and their attitude to giving up smoking with the aim of
evaluating the phase of tobacco abandonment that they
are on according to the process of change in Prochaska
and DiClemente’s Stages of Change model [33].
Once the informed consent form has been signed each
patient will be randomly assigned to the control group
or the intervention group, according to the following
scheme:
 Control group: brief advisory session to help give up
smoking [36]
 Intervention group: brief advisory session on giving
up smoking plus measurement of CO exhaled for
CO-oximetry
Sample size
Meta-analyses have shown that around 5–6 % of
smokers stop after the brief advisory session from a
physician [36]. A 13 % increase in the cessation rate for
the brief advisory session plus CO-oximetry over the
brief advisory session alone is considered clinically rele-
vant. The sample target size is, therefore, 112 patients,
Fig. 1 Flowchart of the study
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with 56 patients in each group of the trial. Allowing for
up to 10 % loss to follow-up, this would provide 80 %
power to detect a 13 % difference in smoking cessation
outcomes at a two-tailed significance level of 5 %.
Blinding
This was an open clinical trial. Only those assessing out-
comes were blinded after assignment to interventions.
Random allocation to study arms
Computerized allocation to each of the study groups is
done in advance. The assignment sequence is generated
by a person who is not responsible for determining pa-
tient eligibility. By the nature of the interventions nei-
ther the researchers nor the patients can be blinded to
the assignment.
Intervention
At the baseline visit (visit 1) patients included in the
study control group will be given a brief advisory ses-
sion about giving up smoking. This will be firm, con-
cise, personalized (trying to find the most important
motivation for each patient) and appropriate to the
phase towards cessation they are in. This will provide
information about the negative effects of tobacco on
their health and explain the main advantages of stop-
ping smoking [36].
Patients included in the intervention group will receive
the brief advisory session, as with the patients who be-
long to the control group, and in addition, CO-oximetry
will be administered to them. This exploration allows
one to know the amount of CO that the subject has in
their body. The patient will take a deep breath and hold
it for 15 s, then a slow, long and complete exhalation
will be made. After a few seconds the oximeter indicator
becomes stable and marks the exact number of particles
per million (ppm) of CO that the subject has in the air
they breathe. Follow-up visits will take place at 3 months
(visit 2), 6 months (visit 3) and 9 months (visit 4). At
each of these moments the anti-smoking advice will be
repeated in the control group and anti-smoking advice
plus CO-oximetry repeated in the intervention group
(Table 2). At the 12-month (visit 5) visit, the anti-
smoking advice will be given to both groups as well as
CO-oximetry.
Independent measures
From each patient included in the study the following
variables will be recorded (Table 1):
1. Donor characteristics: age (years), gender and type of
donor (deceased versus alive)
2. Recipient features:
 Sociodemographic variables: age (years), gender
 Chronic kidney disease-related risk factors:
primary kidney disease, current treatment,
previous transplants, cold ischemia time
 Pre-transplant cardiovascular risk factors: weight
(kg), height (m) and body mass index (kg/m2),
basal cholesterol, systolic and diastolic pre-
transplant blood pressure. Hypertension is defined
as blood pressure above 140/90 mmHg. Pre-
transplant hypercholesterolemia is considered as a
cholesterol value above 200 mg/dl. Cardiovascular
events before the transplant, tumors prior to
transplant, smoking exposure prior to transplant,
pre-transplant diabetes mellitus, and left ventricular
hypertrophy will also be recorded
 Post-transplant cardiovascular risk factors: body
mass index (kg/m2), systolic and diastolic blood
pressure after transplantation, new appearance
of diabetes mellitus after transplantation, left
ventricular hypertrophy after transplant
 Routine biochemistry on follow-up: creatinine
(mg/dl), proteinuria (g/day), leukocyte count
(number/l), hematocrit (%), hemoglobin (g/dl),
serum albumen (g/dl), triglycerides (mg/dl), total
cholesterol (mg/dl), HDL cholesterol (mg/dL),
and LDL cholesterol (mg/dl)
 Transplantation outcomes in the follow-up:
post-transplant cardiovascular events, acute
rejection episodes, graft failure, and infections
3. Evaluation of use of, and exposure, to tobacco:
At the time of their incorporation in the study, the
following information will be collected from all the
patients:
 Self-reported smoking habit: number of
cigarettes smoked per day and number of years
of being smoker (the pack-years index will be
computed)
 Number of previous attempts to stop smoking
 Maximum period of time elapsed without
smoking
 Consumption of tobacco between their family
and/or circle of friends
Both at baseline and during follow-up at 3, 6, 9
and 12 months, the following information will be
collected from each patient:
 Self-reported use of tobacco and number of
cigarettes smoked per day
 Urinary cotinine test
 Stage of change, according to the Prochaska and
DiClemente’s Stages of Change model
(precontemplation, contemplation, preparation,
abandonment) [33]
 Nicotine dependence measured by the
Fagerström test [35]. This test is used to
evaluate the degree of physical dependence
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on nicotine. It consists of six items with two or
four possible answers. The score ranges from 0 to
10. The cutoff points are 4 and 7, where less than
4 means a low dependence, between 4 and 7
means a moderate dependence, and over 7 means
high dependence
 Motivation for giving up smoking, measured
by the Richmond test [34]. This is a test
that has four items with two or four
possible answers. The score range is
between 0 and 10, where item 1 rates
between 0 and 1 and the other items range
from 0 to 3.
Based on this score, patients can be classified,
according to their motivation for giving up
smoking, in four groups: nil or low (0–3 points),
doubtful (4–5 points), moderate (6–7 points), or
high (8–10 points)
The results of the CO-oximetry in the intervention
group will be collected at baseline, at 3 months,
6 months, 9 months and 12 months (visits 1–5). In the
Table 1 Baseline and follow-up measurements








Chronic kidney disease-related risk factors x
Primary kidney disease
Renal replacement therapy before transplantation
Duration of renal replacement therapy before transplantation
Cold ischemia time
Pre-transplant cardiovascular risk factors x
Weight (kg), height (m) and body mass index (kg/m2)
Pre-transplant systolic and diastolic blood pressure (BP)
Pre-transplant cholesterol (mg/dl), high-density lipoprotein (HDL) cholesterol (mg/dl),
low-density lipoprotein (LDL) cholesterol (mg/dl), and triglycerides (mg/dl)
Cardiovascular events before transplantation
Previous malignancies
Left ventricular hypertrophy
Post-transplant cardiovascular risk factors x x x x
Body mass index (kg/m2)
Post-transplant systolic and diastolic blood pressure (BP)
New-onset diabetes mellitus after transplantation
Post-transplant left ventricular hypertrophy
Routine biochemistry at follow-up x x x x x
Creatinine (mg/dl), proteinuria (g/day), leukocyte count (number/l), hematocrit (%),
hemoglobin (g/dl), serum albumin (g/dl), total cholesterol (mg/dl), HDL cholesterol
(mg/dl), LDL cholesterol (mg/dl), and triglycerides (mg/dl)
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control group, CO-oximetry will only be performed at
12 months (visit 5).
Outcome assessment
The effectiveness of both interventions will be evaluated at
3, 6, 9 and 12 months after inclusion in the study. The fol-
lowing outcomes will be investigated (Table 2):
1. Smoking habit cessation, confirmed by a urinary
cotinine test. The intervention will be considered
effective if the test results are lower than 100 ng/ml
2. Self-declared abandonment of smoking habit
3. Reduction in the number of cigarettes smoked per
day self-declared by the patient
4. Variation in the motivational stage of change,
according to the Prochaska and DiClemente’s Stages
of Change model [33]
5. Change in motivation to giving up smoking,
according to the Richmond test [34]
6. Change in nicotine dependence, measured according
to the Fagerström test [35]
In the intervention group, the variation in CO levels in
exhaled air, measured by CO-oximetry, will be regis-
tered. Main outcome will be mean urinary cotinine test
differences between the two groups at 12 months.
Secondary outcomes will include: urinary cotinine test
results at 3, 6 and 9 months, CO-level differences at
12 months, as well as differences in self-reported to-
bacco use, nicotine dependence, Prochaska and DiCle-
mente’s motivational stages of change and the Richmond
test scores at 3, 6, 9 and 12 months of follow-up.
Statistical analysis
Comparability of intervention and control groups will be
checked in terms of the similarity of the distribution of
the variables of interest at baseline. The response that
patients rate, at different time points in the follow-up,
will be compared in both arms of the study according to
the outcomes studied.
The chi-square test or Fisher’s exact test will be used
to compare proportions. Student’s t test will be used to
compare means between groups with a normal distribu-
tion data. The Mann-Whitney test will be used to com-
pare quantitative variables between groups in case of a
non-normal distribution, determined by the Kolmogorov-
Smirnov test.
Correlations between quantitative measurements will
be determined by the Spearman’s rho correlation coeffi-
cient. Matched-pair data analysis will be also computed.
Therefore, to evaluate the differences within each group
at different time points, McNemar’s test and Wilcoxon’s
signed ranks test will be calculated.
Additionally, clinical relevance from intervention will
be studied by calculating the relative risk (RR), relative
risk reduction (RRR), absolute risk reduction (ARR) and
patient number needed to treat (NNT) at different times
during the follow-up. All these measures will be pre-
sented with their confidence interval at 95 %.
A multivariate analysis using multiple linear regression
and logistic regression will be performed, according to
the considered response, to adjust the effectiveness of
the intervention as potential confounders and to deter-
mine which other variables are associated with each of
the results. Variables with statistical significance p <0.10
in the bivariate analysis will be selected to be included in
Table 2 Interventions and measurements in the follow-up after randomization
Basal 3 months 6 months 9 months 12 months
Group allocation and intervention
, Control group:
Brief advice on smoking cessation x x x x x
, Intervention group:
Brief advice on smoking cessation + CO-oximetry x x x x x
Outcome assessment
Pattern of tobacco use (self-reported tobacco use) x x x x x
Smoking cessation rates x x x x
Carbon monoxide (CO) levels in exhaled air by CO-oximetry in the intervention group x x x x x
Carbon monoxide (CO) levels in exhaled air by CO-oximetry in the control group x
Urinary cotinine tests x x x x x
Nicotine dependence (Fagerström test scores) x x x x x
Motivational stages of change (Prochaska and DiClemente’s stages) x x x x x
Motivation for giving up smoking (Richmond test scores) x x x x x
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the multivariate regression analysis. A modeling strategy
of successive steps back will be used.
The degree of agreement between the self-declared
smoking consumption, CO-oximetry results and the test
results of urinary cotinine levels at 3, 6, 9 and 12 months
after surgery will be evaluated. The agreement will be
evaluated by the kappa index.
The validity of self-declared smoking consumption by
patients regarding the results of the CO-oximetry and
urinary cotinine test will be studied. Sensitivity, specifi-
city and positive and negative predictive values will
be determined, together with their 95 % confidence
interval.
All analyses will be performed by intention-to-treat, in
which the total value of randomization will be preserved
and control over confounding reference will be also en-
sured. Analyses will be performed using the statistical
package Statistical Package for the Social Sciences soft-
ware, version 19.0 (SPSS, Chicago, IL, USA).
Ethics
Investigators will ensure that this study is conducted in
accordance with the principles of the Declaration of
Helsinki and ICH Guidelines for Good Clinical Practice.
All participants will be informed of the study and in-
formed consent will be obtained from all participants.
Participant confidentiality will be ensured. The study
will comply with the Data Protection Legislation require-
ments for anonymization of data.
The study has received written approval from the re-
gional Ethics Committee for Clinical Research (Comité
Autonómico de Ética da Investigación de Galicia, EC
registry code 2011/061).
All patients were required to give informed consent to
participate in the clinical trial.
Discussion
According to data published by OBLIKUE the total
cost of a transplant in the first year is €47,136.33.
This surgery is cheaper than dialysis and also gives
the patient a higher likelihood of survival and better
quality of life [37].
However, the transplanted kidney has to be cared for.
Knowledge about risk factors for renal graft loss and its
implications on morbidity and mortality are essential in
trying to prevent this situation which can significantly
harm the results that can be achieved with a kidney
transplant.
In addition to the non-modifiable risk factors that have
an influence on morbidity and mortality, there are others
modifiables, such as tobacco smoking, whose identifica-
tion and control is essential to help improve graft sur-
vival as tobacco smoking is a risk factor that causes
cardiovascular disease and cancer [1] in renal transplant
patients and tobacco consumption also negatively affects
renal function [9, 10].
According to a previous study by our group, patients
who continue smoking after kidney transplantation
increase their risk of cardiovascular events compared to
non-smokers and the incidence of such events also
increases with time of exposure [12].
Of all the interventions that can be carried out, en-
couragement to create a habit of healthy living and the
abandonment of smoking is the simplest and least
expensive option and can be achieved by using a brief
advisory session and conducting CO-oximetry.
Our intervention is aimed at kidney transplant patients
for whom smoking is an added risk factor for impaired
renal function.
Providing direct information related to health effects,
adapted to each individual, and taking into account the
stage of moving towards smoking abandonment that
they are at helps make reduction of tobacco consump-
tion possible. But performing CO-oximetry, a test in
which the patient can actually see a number and a color
that tells them whether they have improved compared to
previous visits, has proved to be more effective in help-
ing successful smoking cessation [38, 39].
In relation to self-reported consumption of tobacco the
validity is questioned because of the belief that smokers
tend to underestimate the amount they smoke [40–43].
As a result of misclassification or deception regarding
self-reports of smoking status, due to information bias,
biochemical measures are recommended to validate self-
reports of smoking behavior among patients who are
participants in evaluation studies [44–46].
Moreover, on the other hand this study will determine
the correlation between self-reported exposure and co-
tinine findings using a urine test strip as well as those
from CO-oximetry. Although CO measurement is not
the best indicator of smoking cessation, at least for
occasional smokers, due to its short half-life, the use of
different outcome measures at different moments of
time will allow us to see the consistency of the results
among them.
Finally, if effectiveness of CO-oximetry is confirmed to
reduce tobacco exposure in this subset of patients, we
would have an intervention that is easy to use, economic
and with considerable implications for cardiovascular
risk prevention.
Trial status
At the time of submission, this trial is in the process of
participant recruitment.
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